Hostname: page-component-586b7cd67f-g8jcs Total loading time: 0 Render date: 2024-12-01T07:21:11.409Z Has data issue: false hasContentIssue false
  • English
  • Français

Comparison between hypo-fractionated dose-escalated volumetric modulated arc therapy and conventional concurrent chemo-radiation in locally advanced head and neck cancer: a pilot study

Published online by Cambridge University Press:  17 May 2019

Ehab Saad Open the ORCID record for Ehab Saad [Opens in a new window] ,
Riham Hani Radwan  and
Eman Abdel Hadi
Ehab Saad*
Affiliation:
Department of clinical oncology and nuclear medicine, Cairo University, Cairo, Egypt
Riham Hani Radwan
Affiliation:
Department of clinical oncology and nuclear medicine, Cairo University, Cairo, Egypt
Eman Abdel Hadi
Affiliation:
Department of clinical oncology and nuclear medicine, Cairo University, Cairo, Egypt
*
Author for correspondence: Ehab Saad, Lecturer of clinical oncology and radiotherapy, Kasr alainy hospital, Cairo, Egypt. Tel: 00201143650739. Fax: 002023653360. E-mail: [email protected]
Get access Rights & Permissions [Opens in a new window]

Abstract

Objective:

In the treatment of locally advanced head and neck cancer (LA-HNC), both dose escalation and hypo-fractionation can improve tumour control rates with uncertain role of addition of concurrent chemotherapy. We aimed at developing a new radiotherapy protocol for patients not eligible to receive the standard concurrent chemo-radiation therapy (CCRT) with little toxicity profile.

Methods:

A total of 63 LA-HNC patients were randomised to receive either: 70 Gy in 35 fx in 7 weeks concurrently with cisplatin 100 mg/m2 every 3 weeks for 3 doses (Arm A) or 74 Gy in 33 fx in 6·5 weeks (Arm B). Volumetric modulated arc therapy plans were created for both treatment arms. We compared the local control (LC), progression-free survival (PFS), overall survival (OS) and acute and late toxicity between the two arms.

Results:

A total of 33 patients were in Arm A versus 30 patients in Arm B with median follow-up 24·2 months. No significant differences in LC, PFS and OS between the two arms. Complete remission occurred in 54·5 and 63·3% of patients in Arms A and B, respectively. All toxicities were significantly less in Arm B than Arm A.

Conclusion:

Slightly dose-escalated hypo-fractionated regimen is safe and feasible and has comparable efficacy and less acute and late side effects than conventional dose CCRT with avoidance of chemotherapy-related toxicities in LA-HNC patients.

Keywords

concurrent chemo-radiationdose-escalated radiotherapyhypo-fractionated radiotherapylocally advanced head and neck cancer
Type
Original Article
Information
Journal of Radiotherapy in Practice , Volume 19 , Issue 2 , June 2020 , pp. 132 - 138
Copyright
© Cambridge University Press 2019

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Footnotes

A written consent was obtained from each patient before recruitment in the study.

The study was approved by the local ethics committee of the department of clinical oncology and nuclear medicine, Cairo University (Ref: a12016).

References

Ko, C, Citrin, D.Radiotherapy for the management of locally advanced squamous cell carcinoma of the head and neck. Oral Dis. 2009; 15: 121–132. doi: 10.1111/j.1601-0825.2008.01495.x.CrossRefGoogle ScholarPubMed
Blanchard, P, Baujat, B, Holostenco, Vet al.Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): a comprehensive analysis by tumour site. Radiother Oncol. 2011; 100: 33–40. doi: 10.1016/j.radonc.2011.05.036.CrossRefGoogle ScholarPubMed
Kouloulias, V, Thalassinou, S, Platoni, Ket al.The treatment outcome and radiation-induced toxicity for patients with head and neck carcinoma in the IMRT era: a systematic review with dosimetric and clinical parameters. Biomed Res Int. 2013; 2013: 1–12. doi: 10.1155/2013/401261.CrossRefGoogle ScholarPubMed
Baujat, B, Bourhis, J, Blanchard, Pet al.Hyperfractionated or accelerated radiotherapy for head and neck cancer. Cochrane Database Syst Rev. 2010; 368: CD002026. doi: 10.1002/14651858.CD002026.pub2.Google Scholar
Pursley, J, Damato, A L, Czerminska, M Aet al.A comparative study of standard intensity-modulated radiotherapy and RapidArc planning techniques for ipsilateral and bilateral head and neck irradiation. Med Dosim. 2017; 42: 31–36. doi: 10.1016/j.meddos.2016.10.004.CrossRefGoogle ScholarPubMed
Yazici, A, Dirican, B, Kara, E.Dosimetric comparison of IMRT simultaneous integrated boost with conventional IMRT treatment planning for head and neck cancer. Acta Phys Pol A. 2015; 128: 236–238. doi: 10.12693/APhysPolA.128.B-236.CrossRefGoogle Scholar
Ozdemir, S, Coban, Y, Akin, Met al.Dosimetric evaluation of nasopharyngeal carcinomas irradiated with different IMRT techniques. J BUON. 2014; 19: 953–957.Google ScholarPubMed
Holt, A, Van Gestel, D, Arends, M Pet al.Multi-institutional comparison of volumetric modulated arc therapy vs. intensity-modulated radiation therapy for head-and-neck cancer: a planning study. Radiat Oncol. 2013; 8 (1). doi: 10.1186/1748-717X-8-26.CrossRefGoogle ScholarPubMed
Li, K, Yang, L, Hu, Qet al.Oral mucosa dose parameters predicting grade ≥3 acute toxicity in locally advanced nasopharyngeal carcinoma patients treated with concurrent intensity-modulated radiation therapy and chemotherapy: an independent validation study comparing oral cavity vers. Transl Oncol. 2017; 10: 752–759. doi: 10.1016/j.tranon.2017.06.011.CrossRefGoogle Scholar
Yi, J, Huang, X, Gao, Let al.Intensity-modulated radiotherapy with simultaneous integrated boost for locoregionally advanced nasopharyngeal carcinoma. Radiat Oncol. 2014; 9. doi: 10.1186/1748-717X-9-56.CrossRefGoogle ScholarPubMed
Leclerc, M, Maingon, P, Hamoir, Met al.Dose-escaltion in head and neck cancer A dose escalation study with intensity modulated radiation therapy (IMRT) in T2N0, T2N1, T3N0 squamous cell carcinomas (SCC) of the oropharynx, larynx and hypopharynx using a simultaneous integrated boost (SIB) appro. Radiother Oncol. 2013; 106: 333–340. doi: 10.1016/j.radonc.2013.03.002.CrossRefGoogle Scholar
Edge, S B, Compton, C C.The american joint committee on cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol. 2010; 17: 1471–1474. doi: 10.1245/s10434-010-0985-4.CrossRefGoogle ScholarPubMed
Landberg, T, Chavaudra, J, Dobbs, Jet al.Report 50. J Int Comm Radiat Units Meas. 2017. doi: 10.1093/jicru/os26.1.report50.Google Scholar
Grégoire, V, Ang, K, Budach, Wet al.Delineation of the neck node levels for head and neck tumors: a 2013 update. DAHANCA, EORTC, HKNPCSG, NCIC CTG, NCRI, RTOG, TROG consensus guidelines. Radiother Oncol. 2014; 110: 172–181. doi: 10.1016/j.radonc.2013.10.010.CrossRefGoogle ScholarPubMed
National Institutes of Health NCI. Common Terminology Criteria for Adverse Events (CTCAE) Versión 4.03. Publish 2010. doi: 10.1080/00140139.2010.489653.CrossRefGoogle Scholar
Schwartz, LH, Litière, S, De Vries, Eet al.RECIST 1.1 - Update and clarification: from the RECIST committee. Eur J Cancer. 2016; 62: 132–137. doi: 10.1016/j.ejca.2016.03.081.CrossRefGoogle ScholarPubMed
Bernier, J, Bentzen, S M.Altered fractionation and combined radio-chemotherapy approaches: pioneering new opportunities in head and neck oncology. Eur J Cancer. 2003; 39: 560–571. doi: 10.1016/S0959-8049(02)00838-9.CrossRefGoogle ScholarPubMed
Overgaard, J, Mohanti, B K, Begum, Net al.Five versus six fractions of radiotherapy per week for squamous-cell carcinoma of the head and neck (IAEA-ACC study): a randomised, multicentre trial. Lancet Oncol. 2010; 11: 553–560. doi: 10.1016/S1470-2045(10)70072-3.CrossRefGoogle ScholarPubMed
Al-Sarraf, M D.The role of concurrent chemo-radiotherapy in patients with head and neck cancers: a review. Gulf J Oncolog. 2007; 2: 8–16.Google Scholar
Negi, P, Kingsley, P A, Srivastava, H, Sharma, S K.Three weekly versus weekly cisplatin as radiosensitizer in head and neck cancer: a decision dilemma. Asian Pacific J Cancer Prev. 2016; 17: 1617–1623. doi: 10.7314/APJCP.2016.17.4.1617.CrossRefGoogle ScholarPubMed
Melotek, JM, Cooper, BT, Koshy, Met al.Weekly versus every-three-weeks platinum-based chemoradiation regimens for head and neck cancer. J Otolaryngol - Head Neck Surg. 2016; 45: 1–9. doi: 10.1186/s40463-016-0175-x.CrossRefGoogle ScholarPubMed
Pignon, J-P, le Maître, A, Maillard, Eet al.Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17, 346 patients. Radiother Oncol. 2009; 92: 4–14. doi: 10.1016/j.radonc.2009.04.014.CrossRefGoogle ScholarPubMed
Wang, X, Eisbruch, A.IMRT for head and neck cancer: reducing xerostomia and dysphagia. J Radiat Res. 2016; 57: i69–75. doi: 10.1093/jrr/rrw047.CrossRefGoogle ScholarPubMed
Teckie, S, Lok, B H, Rao, Set al.High-dose hypofractionated radiotherapy is effective and safe for tumors in the head-and-neck. Oral Oncol. 2016; 60: 74–80. doi: 10.1016/j.oraloncology.2016.06.016.CrossRefGoogle ScholarPubMed
Okunieff, P, Morgan, D, Niemierko, A, Suit, H D.Radiation dose-response of human tumors. Int J Radiat Oncol Biol Phys. 1995; 32: 1227–1237. doi: 10.1016/0360-3016(94)00475-Z.CrossRefGoogle ScholarPubMed
Bentzen, S M.Radiobiological considerations in the design of clinical trials. Radiother Oncol. 1994; 32: 1–11. doi: 10.1016/0167-8140(94)90443-X.CrossRefGoogle ScholarPubMed
Kasibhatla, M, Kirkpatrick, J P, Brizel, D M.How much radiation is the chemotherapy worth in advanced head and neck cancer? Int J Radiat Oncol Biol Phys. 2007; 68: 1491–1495. doi: 10.1016/j.ijrobp.2007.03.025.CrossRefGoogle ScholarPubMed
Fowler, J F.The linear-quadratic formula and progress in fractionated radiotherapy. Br J Radiol. 1989; 62: 679–694. doi: 10.1259/0007-1285-62-740-679.CrossRefGoogle ScholarPubMed
Fowler, J F.Correction to Kasibhatla et al. How much radiation is the chemotherapy worth in advanced head and neck cancer? (Int J Radiat Oncol Biol Phys 2007; 68: 1491–1495). Int J Radiat Oncol Biol Phys. 2008; 71: 326–329. doi: 10.1016/j.ijrobp.2008.01.052.CrossRefGoogle Scholar
Bahl, A, Oinam, A S, Kaur, Set al.Evaluation of acute toxicity and early clinical outcome in head and neck cancers treated with conventional radiotherapy and simultaneous integrated boost arc radiotherapy. World J Oncol. 2017; 8: 117–121. doi: 10.14740/wjon1049w.CrossRefGoogle ScholarPubMed
Fu, K K, Pajak, T F, Trotti, Aet al.A radiation therapy oncology group (RTOG) phase III randomized study to compare hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinomas: first report of RTOG 9003. Int J Radiat Oncol Biol Phys. 2000; 48: 7–16. doi: 10.1016/S0360-3016(00)00663-5.CrossRefGoogle ScholarPubMed
Lee, N, Harris, J, Garden, A Set al.Intensity-modulated radiation therapy with or without chemotherapy for nasopharyngeal carcinoma: radiation therapy oncology group phase II trial 0225. J Clin Oncol. 2009; 27: 3684–3690. doi: 10.1200/JCO.2008.19.9109.CrossRefGoogle ScholarPubMed
Medina, JA, Rueda, A, de Pasos, A Set al.A phase II study of concomitant boost radiation plus concurrent weekly cisplatin for locally advanced unresectable head and neck carcinomas. Radiother Oncol. 2006; 79: 34–38. doi: 10.1016/j.radonc.2006.03.010.CrossRefGoogle ScholarPubMed